share_log
Moomoo 24/7 ·  04/18 11:31

Ocular Therapeutix Shares Are Trading Lower. The Company Announced Topline Results From the Phase 1 HELIOS Study Evaluating AXPAXLI in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Ocular Therapeutix的股價正在走低。該公司公佈了評估中重度至重度非增殖性糖尿病視網膜病變患者AXPAXLI的1期HELIOS研究的主要結果

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論